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Abstract Gaucher disease type I, the most common
lysosomal storage disorder, is associated with immuno-
globulin abnormalities. We studied the prevalence, risk
factors, pathogenesis, and effect of enzyme relation therapy
(ERT) on gammopathies in an adult Gaucher disease type I
cohort (N=63) and related the results to a review of the
currently available literature. Polyclonal gammopathies and
monoclonal gammopathy of undetermined significance
(MGUS) in our adult GD I cohort were found in 41% and
19% of patients. These results are similar to the data from
the literature and correspond to the increased risk of
multiple myeloma (MM) that has been described. The
prevalence of MGUS in our cohort increased with age but
was not associated with disease severity or exposure time.
The serum levels of free light chains of immunoglobulins
were measured and were not found predictive for the
development of MGUS or MM. Levels of pro- as well as
anti-inflammatory cytokines, growth factors, and chemo-
kines, especially those involved in inflammation and B-cell
function, are disturbed in GD I, with the most impressive
and consisting elevations for interleukin-10 and pulmonary
and activation-regulated chemokine. A beneficial effect of
ERT on the occurrence and progression of gammopathies
was suggested from longitudinal data.
Keywords Gaucherdisease.MGUS.Multiplemyeloma.
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Introduction
Gaucher disease type I (GD I, OMIM #230800) is the most
common lysosomal storage disorder. The disease is char-
acterized by a deficiency of the lysosomal enzyme
glucocerebrosidase (glucosylceramidase), which leads to
the accumulation of glucocerebroside in macrophages. The
lipid laden macrophages are called Gaucher cells and are
mainly found in liver, spleen, and bone marrow, resulting in
the most important clinical features hepatosplenomegaly,
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Köln, Germanyskeletal disease, and cytopenia [1, 2]. Since 1991, GD I can
be effectively treated with recombinant glucocerebrosidase
(enzyme replacement therapy, ERT, imiglucerase; Gen-
zyme, Cambridge, MA, USA). More recently, substrate
reduction therapy (miglustat, Actelion Pharmaceuticals,
Basel, Switzerland) has been registered for more attenuated
disease.
An associated feature of GD I is the high frequency of
polyclonal and monoclonal gammopathies [3–22]. In the
general population, polyclonal hypergammaglobulinemia is
a common clinical finding, especially in the setting of
chronic inflammation [23], resulting from an overproduction
of immunoglobulins by plasma cells or B-lymphocytes. An
abnormal increase of monoclonal immunoglobulins or frag-
ments thereof (M protein) can be found in pre-malignant
conditions such as MGUS (monoclonal gammopathy of
undetermined significance) and malignancies of the B-cell
lineage such as multiple myeloma (MM), primary amyloid-
osis, Waldenström macroglobulinemia, chronic lymphocytic
leukemia, and B-cell lymphoma. MGUS is found in approx-
imately 3.2% of adults over the age of 50, increasing to 7.5%
at the age of 85 [24]. Of these individuals, 1% per year
shows progression to MM or a related malignancy. Accord-
ingly, in GD I the risk of MM is strongly increased, as has
been reported in recent studies [25–29]. The risk increases
with advancing age [19, 26], but whether disease severity is
a risk factor is currently unknown.
The mechanism explaining the relationship between GD
and immunoglobulin abnormalities is far from understood.
Studies have mainly focused on cytokines as the mediators
between Gaucher cells, surrounding macrophages and B
cells. Plasma levels of several pro-inflammatory cytokines,
such as tumor necrosis factor (TNF)-α, interleukin (IL)-1,
and IL-6, as well as the anti-inflammatory IL-10, were
found to be increased in GD to variable extents [4, 30–33].
IL-6 and IL-10, as well as hepatocyte growth factor (HGF),
are also involved in the pathogenesis of MM [34]. Other
interesting factors, known to be highly elevated in GD
patients, are pulmonary and activation-regulated chemokine
(PARC) [35], which is involved in initiating the adaptive
immune response. Two studies have reported on the effect
of ERT, with some decrease in polyclonal gammopathies
[6] and a decline in monoclonal M-protein level in a single
case [36].
A relatively new method to identify and monitor
monoclonal gammopathies is by quantifying immunoglob-
ulin free light chains (FLC), circulating κ and λ chains that
are not bound to the immunoglobulin heavy chains, using a
highly sensitive automated immunoassay [37–39]. An
abnormal FLC ratio is an important independent risk factor
for progression of MGUS to MM or a related disorder [40,
41]. In addition, measuring FLC is a sensitive additional
tool to identify monoclonal gammopathies [42]. In GD I, in
which the incidence of MGUS and MM is highly increased
[26], the FLC assay may provide a useful diagnostic tool
for early detection of MGUS and MM.
In this study, we present new data on the prevalence of
polyclonal and monoclonal gammopathies from a large
adult GD I cohort and review the currently available
literature. Second, we studied whether age, disease severity,
and exposure time are risk factors for the development of
monoclonal gammopathies, and if this risk is subsequently
decreased by the administration of ERT. In addition, for the
first time, we investigated the role of FLC as a predictor of
the development of monoclonal gammopathies in GD I.
Finally, the pathogenesis of immunoglobulin abnormalities
in GD patients was studied by means of pro- and anti-
inflammatory cytokine, chemokine, and growth factor
levels and is discussed in relation to previous literature.
Materials and methods
Patients and study design
The files were reviewed and archived serum samples were
collected of all adult GD type I patients that were known
from the outpatient clinic for inherited metabolic disorders
at the Academic Medical Centre (AMC), Amsterdam, The
Netherlands (N=63). The diagnosis GD was based on
measurement of deficient glucocerebrosidase activity in
leukocytes and genotyping [43]. Of the 63 patients, 50
received ERT according to an individualized dosing
protocol [44] and two patients received substrate reduction
therapy. Data on age, sex, splenectomy, genotype, severity
score index, (SSI [45]), creatinine, urea, chitotriosidase, and
the presence and type of immunoglobulin class of mono-
clonal proteins were collected. In patients with a monoclo-
nal gammopathy, exposure time was defined as the number
of years between the diagnosis GD I and the diagnosis
monoclonal gammopathy or start of ERT, whichever came
first. In patients without a monoclonal gammopathy,
exposure time was calculated as the number of years
between the diagnosis GD I and start of therapy, or, in
patients not receiving therapy, the first visit to our clinic.
MGUS was defined as the presence of a monoclonal
immunoglobulin component in the serum (as determined by
protein electrophoresis in agar/agarose gels and immuno-
fixation) at a concentration of less than 30 g/l (IgG, IgA, or
IgM) and normal serum calcium and creatinine [46].
Although histology is required to distinguish osteolytic
lesions caused by MM from those caused by GD, we
decided to classify long-existing lesions as being GD
related. Bone marrow examinations were only performed
when a previously unknown M protein was discovered or
in case of a sharp rise in the levels of immunoglobulins or
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Durie–Salmon [47] and International Staging System (ISS)
criteria [48].
We investigated whether levels of FLC could be
predictive for the development of MGUS and whether
these levels were related to disease severity. Therefore, we
measured FLC levels in serum before start of enzyme
replacement therapy in ten patients with mild GD (SSI≤8)
and ten patients with severe GD (SSI≥9), all without a
monoclonal gammopathy.
In addition, we studied whether changes in cytokine
levels and in FLC and immunoglobulins at baseline and
during ERT were related to the presence or absence of a
monoclonal gammopathy. Therefore, the group of patients
with a monoclonal gammopathy was matched for age, sex,
spleen status, SSI, and the use of ERT to a control group of
GD patients without a monoclonal gammopathy. Serial
measurements of levels of IL-6, IL-10, and PARC at
baseline and after 12, 24, and a median of 114 months of
ERT (range 40–143, whatever was the last determination)
were performed. These were related to changes in immu-
noglobulins and free light chains. Hepatocyte growth factor
(HGF) was measured only at baseline. One patient did not
receive therapy; the first hospital visit was used as T0.
Assays
The standard enzyme activity assay for chitotriosidase with
4-MU-chitotriose (Sigma, St. Louis, MO, USA) as a
substrate was performed at pH 5.2 [49]. Serum κ and λ
FLC were measured using FREELITE reagents (The
Binding Site Ltd, Birmingham, England) on a BNII
nephelometer (Dade-Behring, Deerfield, IL, USA) [37–
39]. Monoclonal FLC were identified as values for κ or λ
that exceeded the reference ranges (κ 6.2–30.2 mg/l, λ
9.1–40 mg/l) and produced an abnormal κ/λ ratio (<0.3
or >1.57). Elevated concentrations of FLC without an
abnormal κ/λ ratio indicate a polyclonal or oligoclonal
increase of FLC. Levels of IgG, IgA, and IgM were
measured by immunoturbidimetric assay (Roche Tina-
quant). IL-6, IL-10, HGF, and PARC were measured by
specific enzyme-linked immunosorbent assays (ELISAs),
according to the instructions of the manufacturer (IL-6 and
IL-10: Sanquin, Amsterdam, The Netherlands; HGF: R&D
Systems, Minneapolis, MN, USA; PARC: Biosource
International, Camarillo, CA, USA).
Statistics
Values in patients are given as medians and ranges.
Differences between patient groups were analyzed by the
Mann–Whitney U test or by χ-square test. Linear mixed
models were used to assess longitudinal changes. Correla-
tions were tested by the rank-correlation test (Spearman
coefficient, ρ). P<0.05 was considered to represent a
statistical difference.
Search strategy
To compare the prevalence of poly- and monoclonal
gammopathies in our cohort with earlier case series and
to study the relative risk of MM, we performed a
MEDLINE search combining the MESH terms Gaucher
disease with either hypergammaglobulinemia, paraprotei-
nemias, and/or multiple myeloma. Literature on cyto-
kines, chemokines, and growth factors in relation to the
development of immunoglobulin abnormalities in GD
were searched combining the MESH terms Gaucher
disease with cytokines and/or chemokines. Case reports
were excluded and only studies that included at least ten
patients were selected.
Results
Patients
The 63 patients had a median age of 53 years (range 25–
83). Thirty-two of patients (51%) were men, and 23 (37%)
were splenectomized. At baseline, median SSI was 8 (range
3–19). The majority of patients had a genotype containing
N370S (95%), with N370S/L444P being the most common
combination (40%). All patients had creatinine and urea
values within the normal range.
At the first assessment, 24 (38%) patients had normal
immunoglobulin levels, 26 (41%) patients had a polyclonal
gammopathy, 12 (19%) patients had MGUS, and one
patient had MM (Table 1, #2). During follow-up (range
5–16 years), none of the patients with normal immuno-
globulin levels or a polyclonal gammopathy developed a
monoclonal gammopathy.
Of the 12 patients with MGUS, two developed MM and/
or amyloidosis after approximately 2 years of ERT (#1 and
3). Patient #1 was diagnosed with MM and amyloidosis
25 months after start of ERT. Pulse therapy with dexa-
methasone was started. Three months after the diagnosis the
patient died from cardiac failure. At 24 months after start of
ERT, patient #3 was diagnosed with amyloidosis. She
received melphalan and prednisone, but died 12 months
later from cardiac failure. Patient #2 was diagnosed with
MM stage IA before start of ERT. During follow-up, IgG
levels gradually increased. After 7 years of ERT, treatment
with reduced dose melphalan and prednisone was started,
which resulted in unacceptable cytopenia. Subsequently,
thalidomide, 100 mg daily, was started with beneficial
effect and stable disease parameters for the last 3 years.
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MGUS, six had a monoclonal, three had a biclonal, and
one a triclonal gammopathy. The most common immuno-
globulin type was IgGκ (Table 1; results previously
presented in part in [26]).
Patients with a monoclonal gammopathy were signifi-
cantly older than patients without a monoclonal gammop-
athy (Table 2). Exposure time to GD, defined as time from
diagnosis until first assessment at our clinic, and severity of
disease measures, assessed by SSI and chitotriosidase at
baseline, were comparable.
A search for studies on monoclonal and polyclonal
gammopathies in GD I resulted in five series [4, 6, 16, 19,
21]. Polyclonal gammopathies were reported in 14–64% and
monoclonal gammopathies in 1–35% of GD I patients
(Table 3).
Five studies have described the prevalence and/or
relative risk of MM in GD patients [25–29]. Table 4
summarizes the data from these studies. The frequency of
MM in these cohorts was 0.4–4.0%, with significantly
elevated relative risks of 5.9–51.1.
Immunoglobulin and FLC levels
In 20 GD patients from the Dutch cohort without a
monoclonal gammopathy (ten with mild disease, SSI≤8,
and ten with severe disease, SSI≥9), FLC were measured
before start of therapy (Fig. 1a). One patient was found to
have a slightly abnormal ratio, and six patients had an
increase in one or both FLC, with a normal ratio. There
were no significant differences in κ or λ FLC-levels
Table 3 Studies on the prevalence of monoclonal and polyclonal
gammopathies in type I Gaucher disease
Reference No. of
Gaucher
patients
Age Polyclonal
gammopathies
Monoclonal
gammopathies
de Fost
et al. [26]
63 25–83 26 (41%) 12 (19%)
Pratt
et al. [19]
16 9–70 6 (38%) 4 (25%)
Shoenfeld
et al. [21]
25 24–78 15 (60%) 2 (8%)
Marti
et al. [16]
23 41.8±18 10 (43%) 8 (35%)
Allen
et al. [4]
22 23–65 14 (64%) 3 (14%)
Brautbar
et al. [6]
507 16–81 14–25% 5 (1%)
Data reflect absolute numbers (and percentage), or, in the study of
Marti et al., mean ± standard deviation.
Table 1 Characteristics of
Gaucher disease type I patients
with a monoclonal
gammopathy
M Male, F female, Sx splenec-
tomy, ERTenzyme replacement
therapy, MG monoclonal
gammopathy, MM multiple
myeloma, MGUS monoclonal
gammopathy of undetermined
significance,Ig immunoglobulin
Patient
no.
Sex Sx Age in 2007 or at
death
Therapy MG type Ig type
1 M N 55 ERT MGUS, progression to
amyloidosis and MM
Free κ
2 M Y 71 ERT MM IgGκ
3 F N 46 ERT MGUS, progression to
amyloidosis
IgGλ
4 M Y 60 ERT MGUS IgGκ
5 M Y 67 ERT MGUS IgGλ
6 M Y 59 ERT MGUS IgAλ, IgGκ
7 F N 67 ERT MGUS IgAκ
8 M N 56 ERT MGUS IgGλ
9 M Y 65 ERT MGUS IgGκ,
IgGλ, IgAκ
10 M N 56 ERT MGUS IgMκ,
IgMλ
11 F N 63 No MGUS IgGλ, IgMκ
12 F Y 75 ERT MGUS IgGκ
13 M N 51 ERT MGUS IgGλ
Table 2 Baseline characteristics of Gaucher type I patients with a
monoclonal gammopathy vs patients without a monoclonal gammopathy
Without MG With MG P
No. of patients 50 13
Age in 2007 or at death 51 (25–83) 60 (46–75) 0.003
No. of male patients 23 (46%) 9 (69%) NS
Years of exposure 11 (0–37) 18 (1–44) NS
No. of splenectomies 17 (34%) 6 (46%) NS
SSI at baseline 7 (3–19) 12 (4–16) NS
Chitotriosidase
(nmol/ml h) at baseline
16,703 (5,409–
132,199)
22,534 (6,417–
62,122)
NS
Data reflect absolute numbers (and percentage) or median (and range).
MG Monoclonal gammopathy, NS not significant, SSI severity score
index
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During follow-up (range 10–16 years), none of the patients
developed a monoclonal gammopathy.
FLC levels were measured in all GD I patients with a
monoclonal gammopathy (Table 1,# 1 –13) and matched
GD I controls (#co1–co13). No serum was available of
patient #12, resulting in two groups of 12 patients. Baseline
immunoglobulin levels were not available in one patient
with a monoclonal gammopathy (#11) and five patients
from the control group (#co4, #co5, #co7, #co11, and
#co13). At baseline, the patients who already had or would
develop MM and/or amyloidosis (#1–3) had strongly
abnormal FLC κ/λ ratios (Fig. 1b). Of the nine patients
with MGUS, one (#7) had an abnormal FLC κ/λ ratio and
four showed elevated levels of FLC κ or λ, but with a
normal FLC ratio. The remaining four patients with MGUS
had both FLC levels as well as a FLC κ/λ ratio within the
normal range. Six of the patients from the control group
had FLC levels and a FLC κ/λ ratio within the normal
range, and six had elevated levels of one or both chains of
Table 4 Studies on the prevalence and relative risk of multiple myeloma in type I Gaucher disease
Reference No. of
patients
Ethnic
background
Age Control
group
No. of patients
with MM
RR of MM
de Fost et al. [26] 131 Mixed 50±14 Dutch Cancer Registry 2 (1.5%) 51.1 (95% CI: 6.2–184)
Lee [25] 239 Mixed Not given None 5 (2%) ND
Shiran et al. [28] 48 Jewish 54±20 511 individuals from the same region 2 (4%) ND
Zimran et al. [29] 505 Jewish 38±21 Israeli Cancer Registry 2 (0.4%) ND
Rosenbloom et al. [27] 2,510 Mixed 33 US Cancer Registry 10 (0.4%) 5.9 (95% CI: 2.8–10.8)
Data on age reflect mean ± standard deviation; data on number of patients with multiple myeloma reflect absolute numbers (and percentage).
MM Multiple myeloma, RR relative risk, 95% CI 95% confidence interval, ND not done
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Fig. 1 FLC levels in Gaucher disease type I patients without a
monoclonal gammopathy with mild disease (SSI≤8) and severe disease
(SSI≥9) (a). FLC levels in Gaucher disease patients with a monoclonal
gammopathy and matched Gaucher disease controls (b). MG Monoclo-
nal gammopathy. The normal range for κ was 6.2–30.2 mg/l and for λ
was 9.1–40 mg/l. The normal ratio for κ/λ was 0.3–1.57
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ratio. During follow-up (range 6–15 years), none of the
patients from the control group developed a monoclonal
gammopathy.
Cytokines, chemokines, and growth factors
At baseline, IL-6 levels were within the normal range in all
but four patients (Fig. 2). There was no significant
difference in IL-6 levels between patients with or without
a monoclonal gammopathy (median (range) 5.9 pg/ml
(1.2–118.4) and 2.2 pg/ml (1.0–57.2), respectively). The
majority of patients (17/24) showed elevated IL-10 levels,
especially in the group of patients with a monoclonal
gammopathy, although not significantly different from the
patients without a monoclonal gammopathy (17.1 pg/ml
(3.9–419.8) and 6.9 pg/ml (1.4–299.3), respectively, P=
0.2). PARC levels were elevated in all GD patients, without
a difference between patients with or without a monoclonal
gammopathy (1,400.0 pg/ml (348.9–2817.3) and 1,078 pg/
ml (411.4–3,552.0), respectively). HGF was within the
normal range in most (16/22) patients, without a difference
between patients with or without a monoclonal gammop-
athy (1,751 pg/ml (926–4,791) and 936 pg/ml (424–9,382),
respectively).
A literature search resulted in seven studies on cyto-
kines, chemokines, and growth factors in GD I patients
(Table 5). In one of these studies, mRNA levels were
measured [32], while in the remaining studies, plasma
levels were studied. If possible, the number of patients with
cytokine levels exceeding the reference range was deter-
mined. In studies in which normal ranges were not provided
[4, 32], we defined the normal range as mean ± 2SD based
on the values of the control group. This was not possible in
the study of Barak et al. [30], in which no detailed data
were provided.
Longitudinal changes
In general, at no time point was there a statistically
significant difference in plasma levels of any of the factors
(i.e., IgG, IgA, IgM, FLC κ and λ, IL-6, IL-10, and PARC)
between patients with and patients without a monoclonal
gammopathy (Fig. 3). In addition, using mixed model
analysis, in neither of the two patient groups, a significant
decrease or increase could be established in plasma levels
of any of the measured factors. The only exception was
PARC, which decreased in all patients, except for one
patient who did not use therapy (#11). Changes in PARC
levels could not be related to changes in levels of
immunoglobulins or free light chains. There were no strong
correlations (i.e., rho>0.6) between any of the factors.
More specifically, immunoglobulin levels remained
stable or decreased in all patients, except for patient #11,
who showed an increase in IgM. This patient was different
from other MGUS patients because she did not receive
therapy. Free light chain levels were more variable, but
clearly FLC levels of patients who were to develop or
already suffered from MM and/or amyloidosis remained
high during ERT (#1–3). Although in most patients no
trends could be distinguished, a consistent decrease in free
light chains and immunogobulins was seen for example in
patient 7, who had an IgAκ M protein. This patient
responded very well to ERT, but other patients with
excellent clinical responses did not always show a similar
decrease in M-protein levels. No relationship was found
between clinical response and decrease in either levels of
immunoglobulins or FLCs.
The course of cytokines did not show a relationship with
changes in either FLC or immunoglobulin levels, although
in the untreated patient with increasing levels of IgM (#11),
also an increase in IL-6 and PARC was noted. On the
contrary, a spontaneous decrease in IL-6 was found in
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Fig. 2 Baseline levels of IL-6, IL-10, PARC, and HGF in Gaucher
disease patients with a monoclonal gammopathy and matched
Gaucher disease controls. Patients with multiple myeloma and/or
amyloidosis are marked by an arrow. Dotted lines reflect the upper
limit of the normal range. IL Interleukin, HGF hepatocyte growth
factor, PARC pulmonary and activation-regulated chemokine, MG
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444 Ann Hematol (2008) 87:439–449patient #2, without therapy for his MM. In patient #1, IL-10
showed a clear decrease after start of ERT but before the
diagnosis amyloidosis and MM was made.
Discussion
In addition to the classical symptoms of GD I, such as
hepatosplenomegaly, skeletal disease, and cytopenia, there
is increasing evidence for existence of co-morbidities,
including increased risk of cancer and abnormal immuno-
globulin profiles. In fact, polyclonal gammopathies and
MGUS occurred in 41% and 19%, respectively, of our adult
Gaucher cohort, which is in line with findings from the
literature (14–64% and 1–35% of patients [4, 6, 16, 19,
21]). In addition, we established that the relative number of
biclonal (3/10) and triclonal (1/10) gammopathies within
the MGUS patients was especially high considering that in
general, biclonal gammopathies occur in 3% of subjects
with MGUS [24], while triclonal gammopathies occur only
very sporadically [50]. The types of immunoglobulin heavy
and light chain immunoglobulins were comparable to the
findings for MGUS in a non-GD population, with a
predominance of IgGκ [24]. As in the general population,
the prevalence of MGUS in our cohort increased with age,
but there was no relationship with disease severity
measures, as assessed by exposure time, baseline SSI, and
chitotriosidase levels. A relationship with age was first
suggested by Pratt et al. [19], who investigated 16 patients
aged 9 to 70 years and established an MGUS in four
patients, all being over 50 years of age. Indirectly, he also
showed an association with severity of disease, since all
patients with splenomegaly had either a monoclonal or
polyclonal gammopathy.
Considering the relatively high risk of monoclonal
gammopathies in GD, the question was raised whether
sensitive measuring of FLC would be useful for the early
detection of monoclonal gammopathies in GD I patients. In
a non-GD population, MGUS patients showed an abnormal
FLC ratio in 44% of cases, which was an important risk
factor for progression to MM or a related disorder [40, 41].
We found that the three GD patients who had or would
soon develop a B-cell malignancy could easily be identified
by their strongly abnormal FLC κ/λ ratios. It was however,
not possible to identify GD patients with MGUS on the
basis of abnormal FLCs since 44% of GD patients with
Table 5 Studies on plasma levels of cytokines, chemokines, and growth factors in Gaucher type I patients
Reference No. of GD
I patients
Age Cytokines Results, no. of patients (%)
with elevated levels
P value for difference with
mean values of the control group
de Fost et al. [26]2 2 2 5 –83 IL-6 4/24 (17%) ND
IL-10 17/24 (71%)
PARC 24/24 (100%)
HGF 6/22 (27%)
Michelakakis [33] 25 NG TNF-α 16/25 (64%) ND
Allen et al. [4]2 22 3 –65 IL-1β Not detectable NS
TNF-α 4/11 (36%) NS
IL-6 19/22 (86%) P=0.0001
IL-10 13/13 (100%) P<0.0001
Lichtenstein et al. [32] 18 NG IL-1β mRNA 5/19 (26%) P=0.0337
TNF-α mRNA 2/19 (11%) NS
IL-6 mRNA 3/19 (16%) NS
IL-8 mRNA 3/19 (16%) NS
Hollak et al. [31]2 9 1 6 –66 M-CSF 24/28 (86%) P<0.001
sCD14 25/27 (93%) P<0.0005
IL-8 25/27 (93%) P<0.0005
IL-6 0/27 (0%) NS
TNF-α 0/27 (0%) NS
Barak et al. [30]2 1 5 –39 IL-1β Mean levels elevated P=0.01
IL-1RA Mean levels elevated P=0.01
sIL-2R Mean levels elevated P<0.001
IL-6 Mean levels elevated P<0.01
IL-8 Not elevated NS
TNF-α 3/21 (14%) NS
Boot et al. [35]5 5 1 2 –67 PARC 55/55 (100%) P<0.0001
Altarescu et al. [56]1 2 1 1 –67 TNF-α 1/12 (8%) NS
NG Not given, ND not done, NS not significant
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Fig. 3 Longitudinal changes in plasma levels of immunoglobulin
heavy and free light chains, IL-6, IL-10, and PARC. Dotted lines
reflect the normal range. Numbers reflect Gaucher disease patients
with a monoclonal gammopathy as described in Table 1 (#1–13) and
matched Gaucher disease controls (#co1–co13) without a monoclonal
gammopathy. IL Interleukin, PARC pulmonary and activation-regulat-
ed chemokine
446 Ann Hematol (2008) 87:439–449MGUS had both FLC levels as well as a FLC κ/λ ratio
within the normal range. A slightly abnormal ratio was not
predictive for progression to MM or MGUS in the single
patient without a monoclonal gammopathy, even after
15 years of follow-up. None of the patients had a decrease
in renal function, implicating that any FLC increase was
indeed due to increased production by plasma cells.
MGUS patients are at risk for developing MM at a rate
of 1% of patients per year. Accordingly, the prevalence of
MM in GD I cohorts of 0.4–1.5% clearly exceeds the
general prevalence of 0.02% (deduced from The Surveil-
lance, Epidemiology, and End Results (SEER) Program of
the National Cancer Institute (NCI)). The assumed diversity
in relative risk of developing MM (5.9 and 51.1) can
simply be explained by age differences in the cohorts: the
highest number of MM patients was clearly established in
the highest age groups.
In a recent consensus report on hematological manifes-
tations of Gaucher disease, the higher incidence of multiple
myeloma in Gaucher disease is acknowledged, and it is
recommended that Gaucher patients should have their
immunoglobulin profile determined at diagnosis and mon-
itored every 2 years (patients <50 years) or every year
(patients >50 years) [51].
Hypotheses on the pathogenesis of immunoglobulin
disorders in GD have mainly focused on the accumulated
glucocerebroside as the causative agent for chronic stimu-
lation of macrophages surrounding Gaucher cells. Cyto-
kines of macrophagic origin could in turn stimulate B cells,
leading to a polyclonal gammopathy which may eventually
transform, directly or via MGUS, into MM. Interestingly,
plasma cells can be found in close contact with Gaucher
cells, suggestive of local interaction (Fig. 4).
In our study, we measured IL-6, IL-10, and HGF, three
factors important for differentiation and/or proliferation of
plasma cells. In addition, IL-6 and IL-10 are also involved
in inflammation and in abnormal bone remodeling in MM,
aspects that are also present in GD. We found elevated IL-
10 levels in most patients, especially those with a
monoclonal gammopathy, and predominantly normal levels
of IL-6 and HGF. Previous studies have also described
increased IL-10 levels [4]. However, findings on IL-6 in
GD I have been variable [4, 30–32]. Inconsistent results
have also been reported for the pro-inflammatory cytokines
TNF-α and IL-1β and the chemokine IL-8 [4, 30–33, 52].
Although not included in this study, increases have been
described for the growth factor M-CSF (monocyte/macro-
phage-colony stimulating factor), the monocyte/macro-
phage activation marker sCD14 (soluble CD14) [31], sIL-2R
(soluble IL-2 receptor), and IL-1RA (IL-1 receptor antago-
nist) [30]. The most impressive increase, both in our study as
well in as in the study by Boot et al. [35], has been found for
PARC, a chemokine that is assumed to be involved in B-cell
differentiation by recruiting T cells and CD-38 negative
mantle zone B lymphocytes to antigen-presenting cells.
In addition to the in vivo studies, it has been described
that murine macrophages that were stimulated in vitro by
glucocerebroside release the pro-inflammatory lymphocyte-
activating factor (LAF = IL-1) in a dose-responsive manner.
This effect was not seen on incubation with galactocerebro-
side, sphingomyelin, and ceramidetrihexoside [53]. Possi-
bly, only minor glycolipid accumulation is sufficient for the
development of B-cell derangement. In fact, a glucocere-
brosidase deficient mouse (L444P homozygote) showed
evidence of B-cell proliferation, as well as elevated serum
IgG levels, even though storage cells were not found [54].
The heterogeneity in plasma cytokine levels that have
been found could be explained by differences in patient
populations and cytokine assays. In addition, it is not
known whether plasma levels adequately reflect tissue
levels. Nevertheless, clearly both pro- as well as anti-
inflammatory cytokine levels are disturbed in GD I. It is
unlikely that Gaucher cells directly induce inflammation,
since Gaucher cells have a phenotype resembling anti-
inflammatory alternatively activated macrophages. More
likely, pro-inflammatory cytokines are produced by sur-
rounding macrophages, with Gaucher cells compensating
for the inflammatory compounds [55].
Now that it is generally accepted that ERT effectively
reduces hepatosplenomegaly, cytopenia and skeletal dis-
ease, the focus should be shifted to new challenges,
including the prevention and treatment of Gaucher associ-
ated co-morbidities. Novel data from our study suggest a
beneficial effect of ERT on the occurrence and severity of
gammopathies in GD patients. First, none of the patients
developed MGUS during ERT. We did see progression of
MGUS to amyloidosis and MM in two patients. However,
since both patients developed these diseases relatively
Fig. 4 Bone marrow aspirate showing plasma cells surrounding a
Gaucher cell in a patient with Gaucher disease type I and multiple
myeloma
Ann Hematol (2008) 87:439–449 447shortly after start of ERT, one could envision that
irreversible changes leading to malignant transformation
had already taken place, and could not be corrected by ERT.
Second, we found that immunoglobulin levels either
decreased or remained stable in both patients with and
without a monoclonal gammopathy. The only patient with a
strong increase in immunoglobulins (IgM) was a patient not
using ERT. A clear influence of ERT on levels of FLC, IL-
6, and IL-10 was not found in our study. A previous report
also found a decrease in immunoglobulin levels during
ERT, although only in patients with a polyclonal gammop-
athy, and not in patients with a monoclonal gammopathy
[6]. Decreases in the levels of IL-10 [4], M-CSF, sCD1431,
and PARC [35] have been described. Nevertheless, to draw
firm conclusions on a possible positive effect of ERT on
gammopathies in GD I, our presumptions should be
confirmed in larger studies. This would require an
international multicenter effort that should aim to establish
whether indeed these long-term complications can be
prevented by ERT and whether this would justify the early
start of treatment.
In summary, there is a high prevalence in GD I of both
polyclonal as well as monoclonal gammopathies, including
MM. The risk of these diseases increases with age.
Mechanisms causing gammopathies remain to be elucidat-
ed, but include the disturbance of cytokine levels involved
in inflammation and B-cell function. ERT is likely to have a
beneficial effect in preventing the occurrence and the
progression of gammopathies.
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